Background and objective The GIPPOZ-study explored the impact of providing drug information on antidepressants to patients (n = 99) with a major depressive episode at time of hospital discharge. One of the clinical outcomes followed up were side effects of antidepressants. This part of the GIPPOZ-study aims at exploring the kind, the frequency and the discomfort caused by side effects experienced of antidepressants. Design Data was collected during a longitudinal multi-centre study at three points in time: at discharge, at 1 month and at 3 months after discharge. Patients answered three questions to monitor side effects of antidepressants: (1) Which side effects do you experience from your antidepressant?, (2) How many days per week do you experience this side effect?, and (3) What level of discomfort causes this side effect (none-mild-moderate-severe)? The reported side effects were classified according to their corresponding 'systemic organ class' of the MedDRA terminology.(1) Setting 11 Flemish psychiatric hospitals. Main outcome measures Descriptive analysis of the side effects related to the antidepressants: type (systemic organ class), frequency (numbers of days per week) and caused discomfort. Results About half of the patients did not report any side effects. The top five of side effects classified according to the MedDRA terminology is: nervous system disorders (29.6%), gastro-intestinal disorders (19.5%), general disorders and administration site conditions (11.7%), psychiatric disorders (11.7%), and skin and subcutaneous tissue disorders (4.2%). The majority of side effects occurred daily (73.5%) and caused mild (31.2%) to moderate (42.6%) discomfort. Conclusions Although half of the study sample experienced side effects of the antidepressants on a daily basis, discomfort was mainly assessed as mild to moderate. Reference
Background and objective The main objective of this study is to compare medication compliance rates in liver transplant patients with increasing time intervals after transplantation, switched from a twicedaily to a once-daily Tacrolimus-based regimen (Prograf Ò vs. Advagraf Ò ). Design Non-interventional, prospective trial. Setting 65 liver-transplant patients with Tacrolimus-based therapy were assigned to three groups with regard to months or years post transplantation (p.t.): Group 1: [6 months \2 years p.t., Group 2: [2 years \5 years p.t., Group 3: [ 5 years p.t. in order to study the relationship of compliance rates and time interval after transplantation. Medication compliance with the immunosuppressive therapy is measured over a 12 months period (each patient taking 6 months Prograf Ò , followed by 6 months Advagraf Ò ) with medication event monitoring systems (MEMS Ò , AARDEX Ltd., Switzerland). Dosing (DC)-, Taking (TC)-, Timing (TIC)-Compliance and Drug Holidays were calculated for each patient by using the data collected with MEMS Ò . The mean rates of compliance were compared between the three subgroups. Main outcome measures DC = percentage of days with the correct number of doses taken, TC = percentage of prescribed doses taken, TIC = number of doses taken within the correct inter-dose interval, DH = period of more than 48 h without drug intake. Results According to a per protocol-analysis, the data of 63 patients were eligible both after the first and the second period of 6 months (Prograf Ò : Group 1: 15 patients (pat.), Group 2: 23 pat., Group 3: [5 years: 22 pat., drop-outs: 3 pat., Advagraf Ò : Group 1: 16 pat., Group 2: 22 pat., Group 3: 21 pat., drop-outs: 1 pat.
, not yet evaluated: 3 pat.). While taking Prograf Ò twice-daily the mean rate of DC was 92% for group 1, 93% for group 2 and 94% for group 3 (P = 0.931). While taking Advagraf Ò once-daily the mean rate of DC was 95% for group 1, 96% for group 2 and 97% for group 3 (P = 0.420). Differences in the compliance rates with the immunosuppressive drug therapy were not significant between the three groups assigned. Surprisingly compliance with the immunosuppressive medication was better the longer liver transplantation was dated back. In all patient groups the resulting DC-and TC-rates were higher than the TIC-rate. Patients seemed to lack awareness for TIC, i.e. patients did not take the drugs in the correct time interval. The correct timing of the evening dose turned out to be more difficult than the correct timing of the morning dose. Background and objective The conventional analgesic treatments including systemic opioids are often inefficient and/or limited because of side effects in treatment of chronic painful wounds (pressure ulcers, ulcers of cancer, arterial leg ulcers, mucositis, etc.). Opioids applied topically (gel, ointment, solution) may cause local and prolonged analgesia by the interaction with opioid receptors on peripheral nerve terminals. We report a study examining the analgesic effects and safety of morphine applied topically to painful malignant wounds.
Design We undertook a study including patients hospitalized in palliative care unit or ambulatory with severe pain of cancerous wounds (scores 3 or 4 on self-assessment scale digital 0 to 4). All patients were treated by morphine gel during 6 weeks. In case of ineffectiveness and correct tolerance, an escalation of dose was previous by the protocol. Patients were not eligible if they had infected or haemorrhagic wounds. Patients could be treated by systemic analgesics including opioids to relieve systemic pain. The protocol was approved by local committees. Morphine gel was prepared by the Pharmacy Department following a manufacturing process and storage conditions validated. Setting Pharmacy Department, Clinical Pharmacy, Palliative Care Unit.
Main outcome measures Assessment of effectiveness by the reduction of the pain score on self-assessment scale digital 0 to 4, assessment of local and systemic safety, dose in milligrams of morphine per application, volume of gel in milliliters per application, frequency of administration.
Results Seven patients hospitalized in palliative care unit or ambulatory with wounds or skin infiltrations (metastatic localisations of solid tumours) of various surfaces (less than 100 cm 2 ) have been included. The volume of gel required by application ranged from 2.5 to 20 ml. The treatment was effective (reduction of at least 2 points on the pain score) for 7 patients. Patients were treated beyond the duration of protocol (6 weeks) and for 6/7 patients until their death. No systemic or local adverse effect has been reported. Conclusions Topical morphine has brought benefits (relief of pain, improvement of general condition) to these 7 patients without common opioïds side effects. The effective doses of topical morphine were lower than usual systemic doses: which suggests that morphine causes analgesia by acting locally and few or no absorption occurs. Nevertheless, a double-blind randomised placebo controlled study needs to be conducted to demonstrate the effectiveness of topical morphine and the few absorption. We undertake a multicenter clinical trial to determine the impact of topical morphine in the management of pain. Contact email audrey.hurgon@curie.net Keywords Clinical outcomes, Hospital pharmacy
OA-05
Temsirolimus: efficacy and safety profile after 10 months use in Strasbourg teaching Hospital Background and objective Since it's marketing authorization in early 2008, temsirolimus is one of the standard treatment of metastatic or advanced, poor prognosis, renal cell carcinoma. It was interesting, with the benefit of 10 months hindsight, to assess efficacy and safety profile of this new mTOR inhibitor in our teaching hospital. Design From January to October 2008, patients who didn't get any benefit from other targeted agents, so as new patients, were offered treatment with Temsirolimus, 25 mg weekly. Setting White blood cell count, chemistry and a physical examination were performed weekly, and tumor response was assessed about every 8 weeks.
Main outcome measures The study of their medical records allowed a comparison with data from the pivot Phase III study conducted by Hudes (HT), with RECIST criteria. Results During 10 months, 10 patients with a median age of 72 years (range 27-89) were treated with Temsirolimus. 50% were categorized in favorable or intermediate risk according to the Motzer criteria and 50% in poor prognosis. Temsirolimus was the third line, range 1-5, systemic treatment offered to these patients since diagnosis of metastatic disease. Previous treatment consisted in interferon (40%), sunitinib (30%), sorafenib (60%). Grade 3 toxicities were rare (10 vs. 67% in HT) and consisted in pneumopathy leading to stop the treatment. Other most frequent side effects were asthenia (60 vs. 51%), worsening hyperglycemia in diabetic patients (40 vs. 25%), anemia (20 vs. 45%) and renal failure worsening (20 vs. 8%). The median treatment duration was 12 weeks (vs. 19), range [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . At the end point of our study, 50% were still treated, 30% were dead, 20% stopped the treatment because of adverse side effect (10%) and disease progression (10%). No patients (0%) experienced objective remission (vs. 8.6%), 50% achieved stable disease (vs. 32% in HT), and 40% progressed. Conclusions In practice, temsirolimus was used not only in patients categorized with defavorable risk but also in patients with favorable or intermediate risk. Toxicities were manageable and fewer than described in Hudes trial. To allow conclusion about efficacy, the patients are still followed up. Comparison with sunitinib, sorafenib and bevacizumab has now to be studied to position temsirolimus against other therapeutics.
OA-06
Erythropoietin prescriptions in orthopaedic surgery Background and objective Guidelines about erythropoietin (EPO) prescription in orthopaedic surgery are scarce. EPO reduces the need for blood transfusions, by increasing haemoglobin levels before planned orthopaedic surgery. The aim of our work was to evaluate indications, treatment strategy and associated treatments (iron) in two sites of orthopaedic surgery in order to standardize practices and to limit prescriptions outside of the reference. Design We conducted a retrospective observational study with a data collection from patients' medical files, using a collection grid. Patients for which syringes of erythropoietin were dispensed by the pharmacy for an orthopaedic surgery between January and December 2008 were selected for the study. Setting Two sites of orthopaedic surgery (Rangueil and Purpan) in Toulouse University Hospital. Main outcome measures Number of prescriptions outside of the reference. Results Among the 74 medical files analyzed, 57 patients were included (28 in Rangueil, 29 in Purpan). The average age was 47.5 years (19-88), sex ratio was 1.2. In Rangueil, 3.6% of prescriptions were made in the indication of marketing authorization (AMM) versus 44.8% in Purpan. In Rangueil, among the 71.4% of patients hospitalized for a planned surgery, one prescription was in the context of AMM. In Purpan, among the 55.2% of hospitalisations for a planned surgery, 81.25% of prescriptions were made according to AMM. The other prescriptions concerned emergency surgeries. Transfusion rates were different between the two sites: 55.6% in case of planned surgery and 75% of patients hospitalized in emergency were transfused in Rangueil, compared to respectively 18.75 and 33.3% in Purpan. The haemoglobin threshold recommended for transfusions was respected for 19% of cases in Rangueil whereas it was never taken into account in Purpan. Iron supplementation was prescribed in 84% of cases in Rangueil, versus 93.1% of prescriptions in Purpan. Conclusions Because prescribing practices are very different depending on sites, we wish to propose a transverse protocol and a prescription form so as to justify and to limit prescriptions outside of the reference. Background and objective The albumin is a plasma protein essential for the regulation and maintenance of oncotic pressure. The high cost, limited availability, the considerable consumption and the adoption about 6 months of a detailed model for the parameters have led to undertake regular monitoring of prescriptions. Design To monitor the correct prescription of albumin, at the hospital wards of Mondovi, Ceva was done by compiling and analyzing the proper motivation. They then analyzed the requirements arrived at the pharmacy during the first half of 2009 to highlight any errors or uses not rational. Main outcome measures Protamine sulfate is the standard heparin antagonist. Its use in cardiac surgery is secured by the automatic monitoring of the heparin effect, but turns out to be complicated in common medical practice all the more this molecule has its own anticoagulation activity.
In our centre, we described an overdose of standard heparin in a 71 year-old man. He had been hospitalized for a stroke and presented with a pulmonary embolism, requiring a continuous heparin therapy at curative dose. One day before the use of protamine, a heparin overdose was clearly defined, with a high activated partial thromboplastin time (APTT). Nevertheless the development of haematuria and the apparition on the medical imaging of the risk of cerebrovascular accidents recurrence led to the decision of reversing the heparin treatment. The dose of protamine was not found in the medical record and 4 h after the injection, although the APTT was still slightly high, the transfer of the patient to the surgery department was possible.
This case leads us to search for guidelines, in order to find a process regulating the use of the protamine in common practice. Different cases have to be set apart. Subcutaneous injection of heparin leads to absorption variability and complicates an antidote use. With a single intravenous administration, the short half-life of heparin has to be taken into account. In the case of a continuous intravenous injection different operating processes can be found in the literature reviews: the dose of protamine to be used can be adjusted according to the heparinemia, or calculated according to the administration flow and the heparin dose given within the 2-4 previous hours, or the heparin dose given within the 4 previous hours, considering the heparin half life. Results In this case we determined protamine dose with the different calculation methods for an administration flow of 600 UI per hour. We found the following results: 1.2, 1.2-2.4, and 1.1 ml of antagonist, respectively, to reverse between 1125 and 2400 UI of standard heparin. Therefore we can notice here an important variability of the theoretical antidote doses, depending on the calculation method. Conclusions The following points have to be emphasized: gathering information about the overdose and its context, limiting protamine use to sever haemorrhages and finally considering a fragmentation of the theoretical dose of protamine in order to reduce dose of antidote to administer at first. The current difficulty lies in the lack of consensus guidelines for protamine use. Background and objective Pulmonary arterial hypertension (PAH) is a rare syndrome caused by increased pulmonary resistance. Approved drugs are efficient, but a multidisciplinary approach is required for treating patients suffering this disease, which are treated in a specialized network including physicians, nurses and pharmacists. We evaluated patients' observance and tolerance as well as their requests in terms of pharmaceutical services Design Our prospective study lasted 6 months from January to June 2009. We discarded drug-naive patients whom started their treatment at the time of the study. The study relied on a 12-item questionnaire performed once on each patient during the time of drug delivery. Questionnaires were filled by a pharmacy resident in the presence of the patient. Setting Pharmacy CHU Conception, 147 Bd Baille 13005 Marseille, France. Main outcome measures Items focused on observance (drug refill frequency, respect of posology, evaluation and causes of non-observance if any), tolerance (nature, frequency and handling of adverse events) and patient's request concerning the service received. Results We delivered treatments for 62 patients among which 37 (60%) filled the questionnaire. The remaining patients had their relatives coming to get the treatment for them due to an important breathlessness or impairment. All patients were extremely observant (97%) and only one patient forgot 2 or 3 takes per month. 87% patients declared no adverse events. 13% declared faintness during the intake of drug, tiredness, or diarrhea. Diarrhea was corrected by temporarily interrupting the treatment according to physician's decision. All patients were satisfied by the medical service. 54% of patients had no particular request while 46% requested extra pharmaceutical services: delivery of drugs for a period longer than 1 month (14%), better availability of drugs (23%), or home-delivery (9%). No request has been made concerning therapeutic education. Conclusions Observance and tolerance are good in patients suffering PAH but nearly half of them were not able to come to the pharmacy to get their treatment. Healthcare was estimated satisfactory and particularly on therapeutic education. Main concerns to be addressed were of logistic nature and efforts are to be made to allow better treatment availability towards this still fragile population. Reference 
Sjukehusapoteket i Å lesund, Å lesund, Norway
Background and objective During a 6-months trial period pharmacists from the hospital pharmacy in Å lesund took part in the treatment team on a medical ward. The aim was to perform an intervention by clinical pharmacists on the ward in order to optimise the pharmacotherapy of the hospitalised patients.
Design The pharmacists reviewed the medication lists of the patients on the ward looking for correct indications, possible contraindications, dosages, interactions, adverse drug reactions and double prescriptions. The detected DRPs were discussed with the medical practitioners during the ward rounds within a multidisciplinary team consisting of a senior practitioner, a junior practitioner, a nurse and a pharmacist.
The outcomes of the pharmaceutical interventions were then documented using the classification system for DRPs according to the Norwegian consensus of 2006 à . Setting A medical ward at the hospital in Å lesund (Helse Sunnmøre). Main outcome measures Amount and classification of detected drugrelated problems. Outcome of the medication reviews and participation in the ward rounds by the pharmacists. Results Of the 231 patients examined 177 had at least one DRP. A total of 323 DRPs were identified. The main problems identified concerned wrong dosages (n = 108), drug choice problems (n = 90) and interactions (n = 59). The recommendations from the pharmacists were accepted by the medical practitioners in 70% of the cases. 11% of the pharmaceutical recommendations were not accepted and 9% were not discussed with the medical practitioners. In 11% of the DRPs the medical practitioners agreed with the suggestions of the pharmacist, but due to various reasons did not have the possibility to change the prescription at that moment. Conclusions The medication review is an appropriate tool to detect DRPs and the Norwegian classification system is suitable to document the identified and discussed DRPs. Background and objective Since the beginning of the year 2009, the consumption of the antibacterial agent linezolid has greatly (92) increased in the intensive care unit of our hospital. Given its high cost, linezolid is given according to local guidelines that include contraindication to other active agents (i.e., glycopeptides). The major aim of our work was to review the clinical use of linezolid in this unit and to compare to the official labelling and to the local guidelines. Design Retrospective study of linezolid prescriptions between June 1st and August 31st 2009. Setting Pharmacy, Strasbourg University Hospital, France. Thirty beds Intensive care unit, Strasbourg University Hospital, France. Main outcome measures patient characteristics, infection localisation, isolated pathogens, duration of therapy and drug-drug interactions according to the French drug agency. Results Over the study period, thirty patients (13 women, 17 men; mean age: 67 years; range: 34-88) were treated by linezolid. Only 10 (33.4%) prescriptions were in accordance with the French official labelling in terms of indications (pneumonia, n = 5; skin and soft tissue infections, n = 5). The other indications included septic and febrile syndrome (26.7%), catheter infections (13.3%), intra-abdominal infections (6.7%), fever in neutropenic patients (10%), bone and joint infections (3.3%), urinary infection (3.3%), food and community toxi-infection (3.3%). Regarding local recommendations, only 10 (33.3%) patients had received glycopeptides before linezolid. The main justification for using linezolid instead of glycopeptides was the alteration of renal function. Twenty-three (76.7%) patients had documented gram-positive infection. Isolated pathogens primarily include Staphylococcus. Seven patients received linezolid as empiric treatment. The mean duration of linezolid treatment was 8 days (range: 1-24). Four patients (13.3%) were treated more than the recommended 14 days. Three potential drug-drug interactions without apparent clinical consequence were recorded: two associations with paroxetin (risk of serotonin syndrome) and one association with rifampicin (risk of decreased activity of linezolid). Co-administration with adrenergic agents was frequently encountered but was clinically judged irrelevant because patients are closely monitored (risk of enhancement of pressor response due to the monoamine oxidase inhibitory activity of linezolid). Conclusions Appropriate use of linezolid was found in a minority of patients of intensive care unit. Adherence to both official labelling and local guidelines were poorly followed in our hospital. The use of linezolid instead of glycopeptides in patients with altered renal function is debatable and could necessitate the reevaluation of local guidelines. Background and objective Primary education is one of the main paths to promote proper knowledge concerning health aspects to children. The aims of the study are (1) to increase the level of parents and children's involvement in health related activities and (2) to teach children of 6-10 years old the basic rules to promote health and to prevent illnesses. Design Starting from September 2009, every month, throughout an entire year, free brochures are distributed in community pharmacies and online. The brochures contain health information, specific for each grade of the primary school. For the first grade, aspects concerning hygiene and nutrition are included. For the second, third and fourth grade we considered to present aspects related to the human body. Each brochure contains a feedback form to assess parents' opinion about the program and the accumulated knowledge of the children. Free mailing and online access are available for the answers.
Setting Chain community pharmacies located in the main cities in Romania.
Main outcome measures The parents' overall opinion about the program; the usefulness of the topic presented in the materials; the number of pages from the brochures worked-out by the children; the accumulated knowledge of children.
Results A number of 1049 feedback forms were received after 2 months. Most of the parents rated the overall program as being very good (89.80%). The information contained by the brochures was considered as being important (67.78%) and useful (30.41%). Only a small number of children worked-out less than three pages of the brochures (2.67%) while most of them worked-out the hole brochure (80.36%). The accumulated knowledge of children was assessed on a scale from 0 to 4 and an average score of 2.03 was obtained. 23.42% scored 0 points and 14.07% scored 4 points. Conclusions Health education for children is rated as being important by the parents. Although the majority of the children worked-out the proposed materials, the level of accumulated knowledge was not as high as expected. More educational programs are needed in order to increase the level of health related knowledge in this segment. Contact email antsuky2005@yahoo.com Keywords Health education in children, Feedback forms, Health related activities, Community pharmacy
PC-11
Improving pharmacy production workflow: how to decrease patient waiting time for chemotherapy Background and objective Traditional dispensing of chemotherapy is based on preparation of individualised doses for each patient, immediately before administration. As the number and complexity of chemotherapy regimens increase, pharmacy production has to rationalize chemotherapy preparation delays. For the Chemotherapy Preparation Unit (CPU), the constant priority is to fit our organization in the hospital day-care unit's workflow, in order to minimize patient waiting time. For this goal, we have analysed the feasibility of separated delivery of our preparations instead of waiting for the whole treatment to be ready to ''be dispensed''. We have thus defined which regimen could be fractionated.
Design Two day-care units were considered (Haematology H, Dermatology D). Patient's inclusions from April to December 2009 were collected retrospectively via the CHIMIO Ò software (Computer Engineering). Setting CPU, Pharmacy, Hôpital Saint-Louis, Paris, France.
Main outcome measures Analysis of prescribed regimens focused on the number of anticancer drugs, shelf-life, and length of infusion of each chemotherapy compound. A minimum time limit of 1 h between two deliveries was defined in order to be able to fractionate regimens, corresponding to the time to preparation. A maximum of 2 deliveries per protocol has been stated. Results Since the CPU opening in April 2009, 3101 prescriptions for an overall of 200 protocols have been collected, 61.6% of them in H day-care unit. In D unit, most prescriptions (80.6%) consisted in monotherapy (dacarbazin, fotemustin, rituximab). In H unit, polychimiotherapy (PCT) represented 52.5% of prescribed regimens. With our criteria, protocols were subdivided in two categories, according to the infusion duration of chemotherapy drugs.
''One-delivery'' protocols included all monotherapies, and protocols consisting in an association of short infusion duration drugs (ABVD, CHOP, etc.), respectively 88.1% in D and 67.7% in H.
''Two-deliveries'' protocols included PCT regimens with long infusion duration. Monoclonal antibodies associated with cytotoxic(s), (such as rituximab, administered in 90 min, and cetuximab), represented 11.9% in D unit, and 28.5% of prescriptions in H unit. Other fractionable regimens included ACVBP, BEACOPP and etoposide/ifosfamide association (3.7% in H unit).
This analysis shows us that the most important criteria to fractionate regimens is the length of infusion for the first or the two-first drugs administered. This length has to be over 1 h 30 min. Conclusions Evaluation of workflow in streamlining the dispensing process has shown to be an essential step to improve the CPU organization. Better efficiency is achieved through coordination between pharmacy and medical wards, particularly in the case of emergency prescriptions. The fact that we could fractionate some regimens can help CPUs to regulate their activities. Contact email nathalie.jourdan@sls.aphp.fr Keywords Implementation, Pharmaceutical care issues, Protocols
PC-12
Pharmaceutical care and medication reconciliation in an orthopaedic ward Use of therapeutic equivalents must balance the medicines' characteristics and patients' specific clinical condition. This implies the clinical pharmacist compromise to the patient by applying standard operation procedures and following-up the patients' clinical outcomes in a systematic and personalized manner (pharmaceutical care program).
Main objective of this study is to characterise and evaluate the impact of using therapeutic equivalents in patients in an orthopaedic ward. . The blood must be put precisely on the strip with both systems otherwise the measure can be distorted. However, deposit sites on sides of the strip of Coaguchek lead an optimal deposit. So we will introduce Coaguchek Ò to the geriatric department, to improve treatment and observance and to give a greater autonomy to patients. A biologist and a pharmacist will assist patients and medical staff to familiarize with this device. Further, we plan an evaluation of this system with patients. In conclusion, user satisfaction is very important because patients will be more observant with an attractive system. Moreover intensive formation of patients must be conducted to ensure that patients are aware of the importance to monitoring INR for dose adjustment. Results The prevalence of adherence to metformin and glyburide were 60.3 and 64.7% respectively. Association between adherence and glycemic control showed that adherent patients had lower HbA1c level than those who are non-adherent (P \ 0.001). The most common barriers to adherence were: forgetting to take doses (38%), fasting in Ramadan (11%), adverse effects (8%), polypharmacy (4.5%) and disruption of routines (3.5%). Conclusions To our knowledge, no such data of Iranian diabetic patients have been published. A significant relationship emerged between good adherence to medication and lower related clinical outcomes prove pill count to be useful in clinical practice to identify non-adherent patients. Further studies should be done to find out efficient interventions to improve adherence. References Background and objective Non-compliance is one of causes of nonrational use of medications and prediction of this behaviour is in the interest of rationalisation of therapy. Until now pilot research on prediction of non-compliance was made in Lithuania. This exploratory study revealed new hypothesis about non-compliance with antibiotic therapy. Design The purpose of this research was to identify possible risk factors that may cause non-compliance. Setting Questionnaire for pilot study was developed according to the WHO recommendations for minimal information about medications to the patient. All of participated patients (N = 36) were from Urology department of Clinics of Kaunas Medicine University. Every of them had to take some antibiotics for treatment or for prophylaxis at home. For most of the patients it was a short-time therapy (from 5 to 7 days). By the end of the treatment those patients were questioned at home about usage of antibiotics; during the visit, there were counted taken/untaken pills of prescribed antibiotics. Current questionnaire was made of two parts: one part is from previous questionnaire made according the WHO recommendations for minimal information about medications to the patient, second part was made from already verified questionnaires as Morisky Medication Adherence Scale, ASK-20 questionnaire and SF-12 questionnaire. We are going to question about 200 patients in this survey. Main outcome measures Data were analyzed statistically by descriptive and comparative statistic analysis by parameter of Pearson's chi square (statistically significant result was when chi square [4, P \ 0.05). Results In pilot study there were 31% of patients who failed to comply with prescribed antibiotic therapy. Several statistically significant risk factors of non-compliance were identified representing both educational and social constrains, most important ones-lack of knowledge about using medications and maximal dose and better knowledge about contraindications; negligence of self-medication with prescription NSAIDs; frequent usage of herbal medications etc. Conclusions Now further investigations are doing to confirm and verify results of pilot study. Primary data of this research will be analyzed and presented during the conference. Background and objective Intravenous (IV) therapy usually requires preparation (dissolving, dilution, etc.) of medicines before administration. These processes, carried out by nurses in hospital wards, present multiple opportunities for errors. The aim of the pilot study was to investigate the incidence and nature of errors, emerge during preparation of aseptic medicines by nurses in the wards of Tartu University Clinics (TUC). Design Observational study was undertaken. Visits were agreed with the head nurses of the departments and the nurses of the wards were informed about the study purposes. All preparations of IV medicines carried out during study were automatically included. Setting The preparation of IV medicines was investigated from November 2008 to April 2009 in the five TUC wards (W1 to W5). Main outcome measures Self-developed data collection form was used to document preparation of medicines. Form included the following questions: description of the prepared drug solution; whether the workspace was prepared and equipment used correctly; the hand hygiene; were the solid drugs dissolved and the drug solutions mixed; marking of the syringe/bottle of prepared medicine. For addition, comments on overall habits on preparation of aseptic medicines were made. Results Overall 99 preparations were observed by the hospital pharmacist during 23 visits, and mostly (64.6%) the dilution of drug solutions was performed. For 75% of cases the nurse collected everything needed prior the drug preparation process and 72% of the cases nurses handled the used equipment correctly. This included the use of single-use tool once and correct disinfection of surfaces, if necessary.
The result showed the lack of hand hygiene and glove use practice. More than 34% (6% in W2 to 100% in W5) of nurses did not perform hand disinfection and more than 44% (10% in W5 to 94% in W1) did not use gloves prior to aseptic preparation of medicines. Besides, 30% of nurses performed hand hygiene and 20% used gloves incorrectly.
Mixing of drug solutions was not performed in 44% of the cases and in 9% of the cases the dissolving process was not sufficient to ensure the full dissolution of the drug substances.
32% (0% in W3 and W5 to 33% in W1 and W2) of syringes/ bottles of prepared medicines were left unmarked. Less than half (43%; 28% in W1 to 80% in W5) of the marked syringes/bottles had the both-name of the substance or formulation and the dosewritten on it. Conclusions Pilot study identified insufficient professional knowledge and working skills of nurses performing preparation of aseptic medicines in TUC. The guidelines and trainings provided by hospital pharmacists would improve the quality of IV antiseptic medicines prepared at wards and reduce the risk of possible errors in preparation of antiseptic medicines. Keywords Drug-related problems, Hospital pharmacy, Nursing care
PSC-01
Comparison between data in the electronic medical records, prescriptions in the Swedish national prescription repository and patients knowledge of their present prescribed treatment Background and objective Patient adherence to prescribed treatment for chronic conditions has been estimated to be on average about 50% (1), drug related problems may cause as much as 30% of acute admittances to hospital care (2) , and the costs have been estimated to be of the same magnitude as the direct costs for pharmaceutical drugs. A reason for lack of adherence to the treatment and medication errors may be that patients with many drugs, especially when changes in the treatment have occurred, may have knowledge gaps on the drugs representing the actual prescribed treatment. E-prescribing, from the physicians' electronic medical record (EMR) directly to the pharmacies, constitute [75% of all prescriptions in Sweden and [70% of patients in Sweden store their prescriptions electronically at the national prescription repository (NPR), accessible from any pharmacy in Sweden. Any new e-prescription will automatically be stored in the NPR.
However, the NPR may contain both prescriptions for the present, actual treatment, prescription duplicates, and prescriptions for previous, terminated or changed treatment. For patients with many medications and/or many changes in the treatment it is obvious that the risk for medication errors is increased.
The objective of the present study was to compare the prescribed treatment in the EMR, the prescriptions in the NPR, and patient's knowledge of her/his present prescribed treatment.
Design Background and objective Patient adherence to prescribed treatment for chronic conditions has been estimated to be on average about 50% (1), drug related problems may cause as much as 30% of acute admittances to hospital care (2) , and the costs have been estimated to be of the same magnitude as the direct costs for pharmaceutical drugs.
A reason for lack of adherence to the treatment and medication errors may be that patients with many drugs, especially when changes in the treatment have occurred, may have knowledge gaps on the drugs representing the actual prescribed treatment. E-prescribing from the physicians' electronic medical record (EMR) directly to the pharmacies, constitute [75% of all prescriptions in Sweden and [70% of the patients in Sweden store their prescriptions electronically at the national prescription repository (NPR), accessible from any pharmacy in Sweden. Any new e-prescription will automatically be stored in the NPR.
However, the NPR may contain both the prescriptions for the actual treatment as well as prescription duplicates, but also valid prescriptions for previous, terminated or changed treatment. For patients with many medications and/or many changes in the treatment it is obvious that the risk for medication errors is increased. The objective of the present study was to compare the actual prescribed treatment in the EMR, the prescriptions in the NPR and patient's knowledge of the prescribed treatment for patients with chronic diseases. Design Cross-sectional study. Patients 18 years of age without cognitive dysfunction, with diagnoses of either chronic heart failure (CHF), diabetes mellitus (IDDM or NIDDM) or arthrosis and a prescribed treatment with 5 drugs in the EMR, scheduled to a follow-up visit at the HCC were invited. Patients giving written, informed consent to participate were included. The prescribed drug treatment in the EMR, prescriptions in the NPR and the patient's statement of the present treatment were compared. Background and objective The development of oral targeted therapies represents an important financial stake for the pharmaceutical industry especially regarding to cancerology for which the standard protocols rely essentially on intravenous cytotoxic chemotherapy. The oral therapies evolution is obviously expanding. Therefore, our target is to point out the evolution between 2002 and 2009 of the oral route in clinical trials of cancerology within our hospital in order to adapt our clinical activity to the therapeutic patients needs. Design We extracted data from PharmEssaiÒ , specific software of clinical trials management. Setting Clinical trials including oral chemotherapies represent currently 50.8% (31/61) of the clinical studies in cancerology, against 37.5% (9/24) in 2002. The oral molecules number increased from 4 to 16. These results are mainly the consequences of the tyrosine kinase inhibitors growth (55.9% of the oral chemotherapy studies), followed by the immunomodulators (18.1%) and the Histone Déacetylase inhibitors (9%). These results predict an increase of these molecules place in the daily therapeutic strategy. Main outcome measures During the clinical trials, patients benefit from a greater surveillance by a specialized medical staff and from a rigorous control of the observance. Moreover, some sponsors develop kits for patients including gloves and practical information about the good use of chemotherapies as the intakes rhythm, the recommendations in case of side effects, of intake forgetting, etc. Therefore, we are homogenizing these practices to all of oral molecules in trial. Results In future, we would like to organize an interview before treatment institution in order to increase the safety of patients and their close relations, cares quality, to make patients aware of the management of toxic wastes, as well as at least one visit of pharmaceutical follow-up (understanding of treatments, management of side effects, etc.). Conclusions If these molecules are effectively marketed, there are the risk of an apparition of a medicine trivialization despite of the fact that it is about cytotoxic drugs, a fall of quality follow-up and a less strict observance; this in the disfavour of patients. These observations prove the interest of a therapeutic education specialized for the cancerous patients and their close relations; a therapeutic education should be organized systematically. Contact email justine.florek@yahoo.fr
PSC-05
Potential drug-drug interactions of highest clinical significance (PDDI) with digoxin endanger patients' mortality in Slovakia The impact of digoxin daily dose T. Foltanova, K. Galková
, V. Husárová
Background and objective Digoxin is safe, inexpensive and well tolerated when dosed appropriately. On the other hand, mostly in older patients, therapy with digoxin is connected with high risk of PDDI. In Slovakia, country with high cardiovascular mortality, effect of PDDI with digoxin and the impact of digoxin daily dose in patients with PDDI on mortality has not been studied yet. The objective was to identify the daily dose of digoxin in high risk cardiovascular patients endangered by PDDI. Design Retrospective analysis of PDDI with digoxin and digoxin daily dose. Setting 849 high-risk cardiovascular patients ((M/F 51.2/48.8%), average age 67.2 years, (55-88 years)), who were enrolled into a prospective trial-HOPE-TOO in Slovakia (2000) (2001) (2002) (2003) (2004) (2005) . Main outcome measures all cause mortality, PDDI with digoxin, daily dose of digoxin. Results High risk cardiovascular patients with PDDI have almost two times higher risk of mortality compared to patients without PDDI (OR = 1.83 (1.33-2.51) P \ 0.001). In our subset the most frequent PDDI were with digoxin, in particular digoxin-furosemid (in average 34.3% of all PDDI per year). In total, during 5 years, digoxin was taken by 31% patients with high cardiovascular risk. Prescription of digoxin had decreasing trend. The average daily dose of digoxin was 0.131 ± 0.007 mg (0.04-0.50 mg). The daily dose of digoxin in most patients was 0.125 mg (median = 0.125 mg). Average daily dose of furosemid in patients endangered by PDDI was 64.52 ± 10.175 mg. The daily dose of furosemid in most patients was 40 mg (median = 40 mg). Conclusions High daily dose of digoxin might be one of the reasons of higher mortality in high risk cardiovascular patients in Slovakia, who are endangered by PDDI of highest clinical significance. Improving risk assessment in digoxin therapy as well as giving proper dosage recommendation by the pharmacist to all patients dispensed digoxin, could prevent digoxin toxicity.
PSC-06
Patients' experiences with generic substitution-a Swedish pharmacy survey This study aimed to evaluate how Swedish drug consumers experience generic substitution, more than 5 year after implementation. Design Survey study with an electronic questionnaire, offered to 1551 pharmacy customers/patients presenting with a prescription on one of the 2688 drugs included. The selected drugs constituted 75% of the total volume of dispensed drugs subjected to generic substitution in August 2007. Setting Fifty-eight Swedish community pharmacies. Main outcome measures Positive experiences with generic substitution; problems and their degree of seriousness; and the reported incidence of medication errors. Consumers' suggestions of improvements to the generic substitution system were also captured. Results Of 1551 respondents (602 male, 949 female), 35% (n = 536) reported one or more positive experiences, the most common being the lower drug price. Sixty percent (n = 932) claimed they had not experienced any problems. Forty percent reported at least one problem related to substitution. Seven percent (n = 109) reported medication errors attributed to generic substitution. Twenty-two percent (n = 342) of the respondents offered suggestions for improvement. The most common suggestions were to revise the criteria for assessing interchangeability between brand-name and generic alternatives and to abolish substitution. Conclusions A majority of respondents do not experience any problems related to generic substitution. A sizeable minority experience problems, partly resulting in medication errors. Over-and undermedication, lack of compliance, and intake of wrong drug or of both the original and the generic were the problems most often reported. Future system changes should consider the importance of revised criteria for generic and brand name interchangeability. Background and objective To demonstrate that a medical concomitant prescription of benzodiazepines and high-dose buprenorphine should not be simply considered, as described in the summary of buprenorphine characteristics, as ''Special warnings and precautions for use'' or ''Interaction with other medicinal products and other forms of interaction'' but also as an ''Absolute contraindication''. Design In the document, after cases of deaths, in which concomitant medical prescription of benzodiazepines and high-dose buprenorphine were described. Setting Legal Medecine Unit/Psychiatric Unit. Design The data were collected retrospectively by pharmacists from medical records. The probability and severity was estimated using the Naranjo Score Algorithm and according to the WHO method respectively. Patients completed the QOLIE-AD-48 questionnaireSlovak version. Patients who agreed to participate provided full informed consent. Statistical analysis was performed by Pearson chisquare test. A P-value of less than 0.05 was considered significant. AEs were classified as serious (pancreatitis after valproic acid, rash after carbamazepine, visual field loss after vigabatrin and gingival hyperplasia after phenytoin). The QOL in our patients didn't vary according to gender and socioeconomic status, but severity of the epilepsy and adverse effects of AEDs were the main influence on QOL (P \ 0.05).
Conclusions Our findings highlight the need to screen and evaluate adverse effects of AEDs which correlates with the QOL in the paediatric population. These data also indicate that pharmacists can play an important role in the process of pharmacovigilance in children with epilepsy. Background and objective Heparin and heparin-like anticoagulants are widely used as curative or preventive treatments of thromboembolic diseases, which are the most common preventable cause of hospital-related mortality. There are however certain precautions, which must be taken to avoid unsatisfactory anticoagulation and risk for haemorrhage, based on attentive medical and biological controls. Our aim was to evaluate whether our local hospital practice was in adequacy in administering appropriate heparin therapy. Design Prescribing and administration of heparins were prospectively evaluated three consecutive day-given to allow the inclusion of all patients hospitalised during the survey. Paediatrics and outpatients were excluded. Setting A French general hospital of 450 acute beds. Main outcome measures Conformance of heparin's utilisation with the marketing authorisations by clinical pharmacists. Results Four hundred and two patients were studied. The mean age was 73.1 (18-101) years old. Over half of patients (234/402) received a treatment with low molecular weight heparin (LMWH), standard heparin (SH) or fondaparinux. LMWH (enoxaparin) represented 83.8% of heparin prescriptions, SH 12.4% and fondaparinux 3.8%. Most patients (79%) were treated for thromboprophylaxis. Only 20% of enoxaparin were injected subcutaneously in abdominal belt, the recommended injection site. Evaluation of creatinine clearance was omitted in one-third of the patients treated, because the weighed of the patients was not made during their hospitalisation. Serious renal insufficiency was observed in 6% of patients (creatinine clearance \30 ml/min). 19 patients had heparin despite relative contra-indication (impaired renal function). The biological monitoring (platelet count) was inadequate for 5 patients. Conclusions Our study reveals that actual clinical practice should be improved to enhance safety and efficacy of thromboembolic disease therapy. The present results coupled to clear and simple protocols were diffused by our local medicines committees to physicians, the nursing staff, the laboratory and the pharmacists. To improve LMWH administration, pharmacists for nurses also elaborated a specific illustrated drug information sheet. Also, this study will be done every year and established as a continuing interprofessional education program. Contact email ybezie@gmail.com Keywords Drug use, Hospital pharmacy, Medical care, Prescribing
Contact email

PSH-02
The use of dinoprostone: from cost to clinical study Background and objective In France, induction of labour (IOL) at term is required in approximately 20% of pregnancies. Dinoprostone (Prostaglandin E 2 ) is commonly used for IOL. Two preparations of dinoprostone exist: a slow release pessary (Propess Ò ) and a gel (Prostine Ò ). As shown in CNGOF's recommendations (National college of French gynaecologists and obstetricians), they are equally effective. The aim of this study was firstly, to make an inventory of dinoprostone's use and secondly, to compare costs of both preparations of dinoprostone. Design We conducted a 3-month-retrospective study. One chair and one secretary are nominated for each meeting. Every case is presented in 5 min by a physician's resident for the clinical part, and a pharmacist's resident for the therapeutic part. Case is then analysed by anaesthetists, surgeons and pharmacists. Direct causes (pharmaceutical drug) and deep causes (care giving organisation deficiency, lack of communication, inadequacy in care givers staff, computerized system order, etc.) are researched and analysed.
After analysis, actions to improve the care are identified and implemented with the designation of a professional in charge of this action and the definition of objectives and monitoring indicators. Conclusions The frequency of MMC (currently twice a year) and the attendance (currently only a few attendance compared to the large number of invitees) should be increased. The aim of MMC is not to research any guiltiness but to understand mechanism of events, to identify contributory factors and deep causes, in order to set up preventive actions. Monitoring of preventive or corrective actions is necessary to ensure benefices of MMC. Background and objective To describe the differences in the medication list when a patient C75 years with Apodos (a specific multidose dispensing system) is transferred from the hospital (Ystad Hospital, ward 4 and 7) to primary care in the spring of 2009. Design The first 25 patients C75 years with Apodos who were discharged from each ward from April 1, 2009, were included. Setting Ystad Hospital. Main outcome measures The list of medication from the hospital was copied after discharge and compared with the updated version of Apodos. The discharge information to the patient, discharge summary or any written medication report was examined to see if any differences could be detected. If the explanation of the identified differences were described they were not considered as transmission differences. The assessment was made in consultation between the clinic pharmacist and a doctor. None of the doctors responsible of discharging the patients were aware of the analysis. Results Apodos was updated at discharge in 48 of 50 patients. Of 18 medication reports studied, there were errors in 16 of these compared to the updated Apodos. A total of 618 drugs (of which 149 as needed drugs) were examined, 113 drugs (including 36 as needed drugs) differed from the hospitals medication list. Conclusions Leaving a medication report to patients with Apodos should be avoided provided that the medication changes are documented in the medical journal and described in the discharge information/summary. This will increase patient safety in regards to the list of medication at hospital discharge. This analysis will be discussed by the team of doctors involved, as a basis for changes. Following the same method this will be repeated during the same period next year. Background and objective Elderly HIV-infected patients may present particularities on both disease evolution and morbidity, as compared to younger patients. Moreover, elderly patients are more likely to take numerous medications due to their age-related condition. VISAGE is a French multidisciplinary study group focusing on elderly HIV-infected patients in order to evaluate and improve their therapeutic care. Our study (Visage 1) aimed to analyse potential drug interactions between antiretroviral drugs (ARV) and other products taken by elderly HIV-infected patients. Design This 6-month prospective study involved patients treated for HIV infection and aging more than 60 years at the time of the study. Patients were to fill an anonymous self-questionnaire for reporting their ARV, diseases other than HIV infection, drugs or products regularly taken other than ARV. Observance has been evaluated using a visual analogical scale graduated on 10. Analysis of drug interactions relied on the French drug agency (Afssaps) thesaurus by using the tool available on the website www.theri aque.org. Setting Hospitals or physician offices located in the south of France.
Pharm World Sci (2010) 32:670-689 683
Main outcome measures Clinically relevant drug interactions and level of severity. Observance on ARV and concomitant drugs.
Results 25 women and 70 men filled 95 questionnaires. Median age was 65.3 ± 5.2 years. Treatment of HIV infection was a combination of three ARV for 85% of patients. Among patients, 94% had concomitant treatment with non-ARV drugs (4.6 ± 3.3 drugs/patient) mainly prescribed for a cardiovascular mean. Paracetamol was the most frequently used concomitant drug. Other products used were sexual stimulants and vitamins. Clinically relevant drug interaction occurred in 45% of prescriptions and involved non-ARV drugs. Two associations were found contra-indicated ''ritonavir + alfusozine'' and ''protease inhibitor + simvastatin''. Observance was as high as 9.9 ± 0.4 for antiretroviral drugs, and 9.8 ± 0.6 for the other drugs.
Conclusions Drug interactions were less frequent and less severe than expected in this population. Physician's awareness of concomitant drugs taken by the patient is crucial since most clinically and severe interactions occurred between ARV and non-ARV drugs. Observance was extremely high as compared with the rate usually described for the general population of HIV-infected patients.
Contact email adarque@ap-hm.fr Keywords Clinical outcomes, Drug use, Drug-related problems, Pharmaceutical care issues
PSH-06
Implementation of a medicinal error review Background and objective Drug prescription, dispensation and administration phases can lead to a medication error and if subsequent checks do not permit to detect it before the patient can be reach. We related a medication error in our hospital. Temozolomide, an oral chemotherapy drug (5 capsules packaged in a bottle) was dispensed for a patient for 5 days, from Thursday to Monday. A new prescription for the same patient and for the same drug arrived at pharmacy on Friday. Some capsules dispensed on Thursday were missing. The problem was to know if the patient had received an overdose. In the doubt, drug was not given. Through this experience, we proposed to set up corrective actions. Design This approach is based on a retrospective analysis of the event: description of the therapeutic network, data analysis, improving measures. Setting We targeted different hospital health-care professionals involved in the case (doctors, pharmacists, nurses and quality control manager) and established a workshop. Main outcome measures We had to list and to prioritize the main causes of the medication error: deficiencies in the packaging unit, issued without nominal dose, absence of certainty of administration, everyday acceptance of taking oral chemotherapy, different supports of prescription (chemotherapy IV or oral), premises and equipment not adapted, deficiencies of safety and evaluation of the therapeutic network.
Results Of the analysis of the medication error ensues from improvement measures. Industry has just created a new presentation of temozolomide to provide greater convenience and safety: a unitdose packaging (single dose in a no reusable container). Oral chemotherapies have to be taken in presence of a nurse for hospitalized patients. We are looking for a unique standardized support of drug prescription, dispensation and administration. A daily dispensation with dose distribution must be implemented, with adapted equipment. We also have to reinforce our quality indicators. At last, we set up a medication error review to assess clinical risk management in our hospital. Conclusions This error allowed us to propose implementation of corrective actions and creation of an iatrogenic and drug errors review in our hospital, to avoid any errors of medicinal care and to increase patient safety. Contact email audrey.decottignies@free.fr Keywords Drug dispensing, Drug-related problems, Hospital pharmacy, Implementation, Pharmacist behaviour
PSH-07
Clinical audit on the use of antifungal agents in a teaching hospital in the UK A. Hamad Background and objective The frequency of fungal infections continues to increase. Recently, some fungi species showed resistance to some elite antifungals. New antifungal guidelines were implemented at the hospital on 1st May 2009, mainly for the management of Haematology/Oncology patients. This audit aims to investigate the current prescribing practice of antifungal drugs and to determine whether compliance with the new guidelines is being exercised or not. Design A prospective audit was conducted, in which all patients who were prescribed any systemic antifungal drug were included. Data were collected on the wards between 29th June and 12th July 2009, from patients' medical-notes, electronic-patient-records, and drug-charts. Setting Guy's and St Thomas' NHS Foundation Trust (GSTFT), which is a 1100-bed Trust consists of three hospitals; Guy's Hospital, St Thomas' Hospital, and Evelina Children's Hospital. In 2008/2009, 99,000 patients were admitted and 566,000 patients were seen in the outpatient clinics. A further 145,000 patients were treated in the emergency departments. Main outcome measures The primary outcome was the proportion of antifungal prescriptions that complies with hospital antifungal guidelines and standards. Secondary outcomes included frequency of prescribing for each antifungal drug, the diagnostic criteria used to diagnose fungal infections, type and location of the causative fungi, and clinical outcomes for the patients who have finished their treatment courses. Results Thirty-two patients were included, for whom 42 antifungal courses were prescribed (25 for treatment and 17 for prophylaxis). 63% of patients were Haematology/Oncology patients. The overall compliance was shown in 55% of prescriptions (73% in Haematology/Oncology prescriptions and 25% in other prescriptions, P = 0.002). Fluconazole was the most commonly used (38%) among the six prescribed antifungals. Candida species were the most identified fungi (61%) among infected patients, while chest was the most infected area (44%). Conclusions This audit allowed assessing the use of antifungal drugs in GSTFT which showed a low level of compliance with hospital guidelines. The significant difference in compliance between Haematology/Oncology prescriptions and other prescriptions highlights the need for expanding the guidelines applicability to include all hospital prescribers. Since the guidelines were recently implemented, the awareness about their issuing and the importance of complying with them should be increased. Conclusions Number of adverse drug reactions reported by our paediatrics wards was influenced by several factors. First, usually only severe or rare events were spontaneously reported by physicians. Second, the prolonged hospital stay, the pharmaco-therapeutic groups of drugs, and the polypharmacy also play a significant role. More ever, the reports are provided spontaneously. To increase detection of adverse reactions or events questionnaires and chart reviews should by implemented. Contact email kakosova@dfnsp.sk Keywords Drug-related problems, Hospital pharmacy
PSH-09
Improving medication safety by patient empowermentillustrated medication schedules during hospital stay Background and objective Today various methods can be used to improve medication safety in hospitals. However patients themselves are often not involved in activities designed to improve the medication administration process. In this project patients were empowered by providing individualized medication schedules including colour photographs of the oral medication. Thereby patients were more easily able to take an active part in identifying their drugs and proper drug intake during their hospital stay. In Germany hospitals are obliged to provide inpatients' chronic medication during their hospital stay. At hospital admission the patient's medication is switched to drug products listed in the hospital's formulary. Unit-Dose-Systems are seldom practised in German hospitals. In general nurses fill the oral medication in 24 h-dosette boxes. The oral medication supplied may look different to medicines taken at home. Therefore inpatients can not identify their medication and they do not know the newly prescribed drugs added for example after surgery. Design Survey.
Setting Department of Cardiothoracic and Vascular Surgery. Main outcome measures An illustrated medication schedule was developed in MS Access Ò . The schedule includes colour photographs of each oral medication along with the brand name, INN-name, time and method of administration, indication and specific information as required. After cardiac surgery a clinical pharmacist hands over the patient specific medication schedule and explains medication changes. Patients are informed about the indications of the drugs, side effects of new drugs and which changes are to be expected at discharge. Patients' questions are very welcome and answered by the pharmacist. Shortly before discharge a questionnaire was given to 28 inpatients who received the medication schedule. Results 65% of the patients took the drugs as recommended in the schedule. 57% were able to identify their medication. 61% knew the indication of their medication and 74% were more motivated to take their medication as prescribed. 87% of the patients would like to have an illustrated medication schedule again during another hospital stay. 64% thought they could manage their drug therapy better with the illustrated medications schedule. It took about 5 min to prepare the individualized medication schedule and another 10-15 min to inform/ educate the patient. Conclusions The medication schedule is prepared by a pharmacist who takes the opportunity to detect potential medication errors. During hospital stay inpatients are able to identify their medication in the dosette by the colour photographs in the medication schedule. Background and objective As a clinical professional, the pharmacist plays a key role in monitoring pharmacotherapeutic outcomes of patients. The aim of this study was to evaluate the clinical pharmacy recommendations made from the implementation of an unit-dose drug distribution system (UDDDS) to hospitalized patients. Design Uncontrolled intervention study consisting on prospective monitoring of drug therapy of patients hospitalized during January and December 2009, based on daily validation of prescriptions received in pharmacy, detecting potential drug-related problems (DRPs), confirmed or discarded with the analysis of medical records and interaction with health care team and patients, and later recommend, if it was appropriate, modify the treatment plan. Setting Sub-department of Pharmacy and clinical departments of Hospital Regional Valdivia, Valdivia, Chile. This is a high complexity-hospital with 524 beds. Main outcome measures Type of DRPs intercepted, drug involved, number of clinical recommendations made and acceptability. Results Over a 12-month period, there have been identified 127 DRPs with a percentage of acceptance of clinical recommendations made of 82%. 41% of recommendations were aimed to improving the effectiveness of drug therapy and 59% to reduce the risk of toxicity. These recommendations included: change dose/dose range (69%), suspend medication (12%), switch to drug available (6%), change route of administration (6%). DRPs were mainly related to antimicrobial pharmacotherapy (61%), involving mostly overdose (46%), followed by underdosing (25%) and inadequate drug (13%). On the other hand, were reported 59 adverse drug reactions (ADRs), involving mostly antineoplastic (38%), antibiotics (26%) and antiviral (15%). Of ADRs, skin reactions were the most frequent (37%), followed by liver damage (19%) and gastrointestinal disorders (16%). With regard to the severity of ADRs, 39% was classified in the severe category, according to the WHO definition. Clinical Departments with the highest number of DRPs detected corresponded to Internal Medicine (62.2%), Traumatology (14.2%) and Pediatrics (10.3%). Conclusions This activity has led to better coordination and communication with technical and professional team, systematic monitoring of hospitalized patients receiving pharmacotherapy, integration to team patient care, incentive in the reporting of suspected ADRs and to detect potential or actual DRPs and solve them together with medical team, working in this way in the provision of more adequate and safe therapy. References 
PSH-11
The part of the pharmacist in pharmacovigilance and drug safety: about 6 cases of shallow vein thrombosis after iron injection Step by step, the pharmaceutical team led various investigations to understand and control this sudden phenomenon. Design The medical records analysis allowed for a deeper investigation of the pharmacovigilance files before sending them all to the Centre Régional de Pharmacovigilance (CRPV): prescribed doses, batch numbers, chronology and co-prescribed medication. A review of the summary of product characteristics and an interview of the nurses were necessary to assess the correct use of the drug: dosage, preparation and administration methods. Setting Given the scorching heat of this season, the manufacturer was asked for a physicochemical analysis of the samples from the pharmacy and the units. Moreover, a temperature assessment was performed in the storage areas. Main outcome measures To secure the system, a withdrawal of the vials from the common batch was ordered. A second clinical and biological review of the medical records was carried out, to try and find a risk profile in our cohort. Results The 6 women, aged from 23 to 35 years old, who were hospitalized in the obstetrics and gynaecology department (three different units), all received one or more vials from a common batch of VENOFER Ò . The indications (four post-partum anaemia, one due to pregnancy, and one post-operative) and maximal doses (300 mg over 48 h) were respected. The preparation (extemporaneous, maximal volume 100 ml per 100 mg of iron) and infusion (intravenous, dose rate of 3.5 ml per minute) were done correctly. No interactions between the medications were detected. The temperature assessment showed some heat peaks at 26°C in 2 units. The vials analysis did not highlight any damages. Just one patient had a higher risk of thrombosis. The CRPV did not register similar reports in France. The oral statement of the nurses about their practices is not confirmed by the medical files because they are often incomplete. In previous summers, there were no problems with VENOFER Ò . Conclusions For each patient, the outcome was favourable despite the inconvenience that was caused and the prolonged hospital stay. The teamwork of the pharmacists, nurses and doctors ensured a safe management and control of the situation. A written protocol was drawn up to reassess the importance of good practices and the current arrival of computerized prescriptions with standardized protocols will increase safety even more. Background and objective Intrathecal injection of methotrexate, cytarabin and corticoid, like hydrocortisone, is used for acute lymphoblastic leukaemia. French health institution (AFSSAPS), after reported cases of errors, emphasized the need to secure intrathecal injection. Design We offer a system which avoids those errors in case of preparation in centralised unit. Setting Given the significant lack of information on stability of the three drugs mixed together, we limited it to 1 h after preparation. This short amount of time creates a difficult coordination between preparation, transport and administration. Main outcome measures Our system increases the stability of preparation while guaranteeing an optimum security. Results Bibliographic researches showed that the stability of methotrexate, cytarabin and corticoid diluted separately in syringe with 0.9% sodium chloride, at room temperature, is longer than 24 h. Once mixed, the stability decreases. To extend the expiry, those drugs must be prepared in three individual syringes. We use luer-luer connection device fixed on the larger syringe (containing cytarabin), which allows protected transfer and mix of the three drugs right before administration. The mix is made in the following way: the content of the 1 ml syringe (Méthotrexate) and then the content of the 3 ml syringe (corticoid) are transferred in the 5 ml syringe (cytarabin) by connecting two syringes thanks to luer-luer device. An extra air volume in the top of the corticoid syringe allows pushing all the volume in the last syringe.
With this system, those drugs can be administrated up to 24 h after individual preparation of every drug, without any difficulty of coordination. Moreover, we put the three filled syringes in pockets with a special colour and three different labels giving the identity of the patient, mentions ''for intrathecal injection'' and ''double control before injection needed''. Conclusions This cheap system allows us to have a longer stability adapted to transport and administration, while meeting the user's needs and ensuring the safety of patients. A procedure is available online at each request of injection. Results A 53-year-old woman was treated for a T-lymphoblastic lymphoma with high dose MTX (3000 mg/m 2 ) according to the validated protocol. The patient had already received several intrathecal MTX injections and low dose of MTX (40 mg) without adverse effect. Before the first administration of 5040 mg of MTX, the renal function was normal with an estimated creatinine clearance of 91 ml/min. At that time valaciclovir (1000 mg/day), fluoxetine (20 mg/day) and pantoprazole (20 mg/day) were given concomitantly. According to the protocol, hyperhydration was started the day before. Routine monitoring of MTX plasma concentrations was performed and shown an overdosage at 36-h postinfusion (serum concentration MTX = 20.5 mmol/l) associated with an acute increase in serum creatinine at 292 lmol/l. Alkaline hyperhydration, high rescue doses of folinic acid and carboxypeptidase G2 50 U/kg were given. The outcome was favorable in 15 days (creatinine clearance at 62 ml/min). No error in the dose or in the timing of MTX administration has been noted. This overdosage could be explained by a possible interaction between MTX and pantoprazole as it has already been described with others PPIs. [1] [2] [3] The mechanism of this interaction is still unclear but it has been assumed that PPIs could delayed the renal elimination of MTX and its main metabolite 7-hydroxyMTX by inhibiting renal transporters such as BCRP or the Na ? /K ? /ATPase pump. [4] [5] [6] An upregulation of the hepatic MRP3 protein by PPIs leading to an increase of the MTX efflux from the liver to the blood has also been suggested. 4 Moreover some genetic polymorphisms were also associated with a modification of the metabolism of MTX resulting in an increase of MTX toxicity. 7 Conclusions With pharmacist advice, this case led medical teams to change their practice with a systematic discontinuation of PPI or a switch for ranitidine when patients are treated by high dose MTX. Drug-drug interactions with antineoplastic drugs are not often reported. Pharmacists can help physicians to optimise patient treatment by analysing these prescriptions and by performing a systematic literature research. Background and objective The Swanson implants, a digital silicone implant, have been used since the 1960s for replacing finger joints in patients with degenerative or advanced rheumatoid arthritis. Complications of silicone elastomer finger joint prostheses are wellknown (1) but lymphadenopathy seems to be an unusual complication: Less than fifteen cases have been reported in the literature and the last one was described 17 years ago. (2) However, this side effect occurred in a patient followed by the rheumatologist in Saint Antoine Hospital. Design Case report. Setting Department of Rheumatology-Saint Antoine Hospital, Paris. Main outcome measures Clinical examination, blood chemistry, haematologic, cytomorphological and histological parameters were performed throughout the patient's follow-up. Tolerance was assessed. Results A 80-years-old woman had been followed at frequent intervals for rheumatoid arthritis diagnosed 24 years ago. The 2nd, 3rd, 4th and 5th left metacarpophalangeal joints were replaced with Swanson silastic implants in July 2000. Outcomes of surgery were good, it lead to a better mobility and no more pain. On routine examination in November 2007, she was found to have a nontender, rubber left axillary lymph node measuring 15 9 30 mm. Except this single lymph node, clinical examination was unremarkable. Two suggested diagnosis were lymphoma and breast cancer.
However these were quickly ruled out by all investigations. Haematologic parameters and the para-clinical examination were unremarkable.
Node excision was performed in September 2009. May GrunwaldGiemsa coloration showed foamy macrophages containing vacuoles which suggesting granulomatous pathology. At histological examination, multinucleated giant cells and granulomas were found, surrounding empty space with thin strands of residual silicone.
The axillary lymph node is therefore believed to result from a leakage of silicone from her Swanson implants in her left hand even if the implants were unbroken radiographically. The clinical pharmacist warned the clinician about this side effect. The Swanson implants were not removed because of the good tolerance. Conclusions We describe a case with silicone-induced axillary lymphadenopathy 7 years after joint arthroplasty. The last case report was published in 1993 which can easily explain the lack of knowledge by clinicians. This case was highlighted by the clinical pharmacist who is also in charge of medical device in France. Lymphadenopathy is an unusual complication but probably more common than reported in literature. Indeed, this may be a underdiagnosed complication due to a lack of awareness by clinicians involved in patient's follow up. Pharmacist's medical device skills may be helpful for avoiding sparring exams or misunderstanding. The development of new prothesis are underway but still manufactured in silicone. Contact email pau.rascle@hotmail.com Keyword Drug-related problems
PSH-16
Secondary use of research data on prescribing errors M. P. Tully Background and objective Conduct of large scale prescribing error research usually requires large numbers of pharmacists in multiple hospitals to collect data (1). Little is known about how the hospitals would like to use their own analysed data if they were to get it back. This study identified the plans of hospitals to use the data they collected, received in a collated form from the University as part of their involvement in a large research study. Design Collated data from a single collection day was provided to the hospitals. Semi-structured telephone interviews with senior clinical pharmacists. Interviews were recorded, transcribed and responses collated into tables to allow thematic analysis Setting Pharmacy departments of 20 English acute hospitals that had participated in data collection for study of prevalence of prescribing errors in in-patients.
Main outcome measures Plans of hospital pharmacy departments to use their collated, validated and analysed prescribing error data that the research team returned to them.
Results Fifteen pharmacists participated (75%). Fourteen hospitals intended to use the data; one hospital wanted more detailed than had been provided. They intended to use it to minimise error rates by providing additional education and training to prescribers. Hospitals differed in their proposed methods; the use of protocols and training sessions were the most popular (eight hospitals). Six hospitals also intended to use the data as a ''bargaining tool'', providing evidence on the impact of pharmacists, allowing additional funding to be negotiated to employ more pharmacists. All planned to present or had already presented the data to senior hospital management.
Conclusions The NHS has made error reduction a priority, with prescribing errors seen as a serious problem. Subsequently, hospitals are expected to both audit and monitor their activity. The provision of data from a research study, collated in a standardised format, which enabled comparison with other hospitals, was valued by all hospitals. They intended to change the provision of educational and pharmacist interventions based on these data. Whether these intentions have actually been translated into reality will be investigated 1 year after all data have been provided to the hospitals. Reference Background and objective Medication errors cause numerous adverse events in hospitals. Recently, the Italian Ministry of Health has distributed a recommendation on how to deal with high-alert medications. The document attributes many tasks to the hospital pharmacist, who is responsible to keep informed ward personnel on how to limit medication errors, and to implement programs with the aim of reducing drug risks. The objective of the present work is to describe an audit program implemented by pharmacists in the wards with the aim of analyzing drug management processes and detect system failures. Uppsala University, Uppsala, Sweden
Background and objective Patient adherence to prescribed treatment for chronic conditions has been estimated to be on average about 50% (1), drug related problems may cause as much as 30% of acute admittances to hospital care (2) , and the costs have been estimated to be of the same magnitude as the direct costs for pharmaceutical drugs. E-prescribing, from the physicians' electronic medical record (EMR) directly to the pharmacies, constitute [75% of all prescriptions in Sweden and [70% of patients in Sweden store their prescriptions electronically in the national prescription repository (NPR), accessible from any pharmacy in Sweden. However, the NPR may contain both prescriptions for the present, actual treatment, prescription duplicates, and prescriptions for previous, terminated or changed treatment. For patients with many medications and/or many changes in the treatment it is obvious that the risk for medication errors is increased.
The objective of was to study the presence of prescription duplicates, double medication and for old, previously changed treatment in the NPR. Design Pharmacy customers over 18 years of age and 5 or more prescriptions stored in the NPR were invited to the study. Customers giving informed consent to participate were interviewed. The prescriptions in the NPR were classified as (a) present actual treatment; Background and objective Health care provision is complex, with many actors, bringing difficulties in ensuring the responsibility for different health care providers is clear. ''The problem of many hands often turns the quest for responsibility into a quest of the Holy Grail.'' (1) Perceived lack of responsibility for a patient between primary and hospital care can lead to non-compliance with drug guidelines. ( 2) The aim of this study was to investigate hospital and primary care doctors' views of responsibility for patients' drug therapy. Design Four audio-recorded focus groups were held with hospital doctors and with primary care doctors. Fourteen hospital and 27 primary care doctors participated. The data were transcribed and analysed from an interpretivist perspective, to capture the physicians' perspective. Data were coded and categorised and similar categories grouped into themes. A mixed focus group was then held with 14 doctors from both primary care and hospital, who had participated in earlier focus groups. This allowed doctors from both settings to discuss the findings from the separate groups and to explore variations in the data. Setting Primary and secondary care in Uppsala County, Sweden. Main outcome measures Doctors' perception of responsibility for the patient's drugs. Results Taking responsibility for the patient's drug therapy was seen as reviewing the patient's drugs and updating the list of medications in the medical record. Nobody had the overall responsibility for the individual patient's drug therapy. Hospital doctors often only took responsibility for their own clinical area. Primary care doctors found it difficult to take total responsibility, especially for highly specialized treatments, even though they described themselves as having a more comprehensive perspective of the patient's drugs than the hospital doctors. Barriers to taking responsibility included time constrains, lack of information regarding prescribing decisions by other doctors, highly specialized or expensive drugs and lack of economic incentives. Conclusions Taking responsibility to review all the patient's medications was perceived as important, but was described as difficult in daily practice. Clinical pharmacists could have an important role in initiating updates of the patient's drugs, thus ensuring that the responsibility necessary for patient safety is taken.
